1. Search Result
Search Result
Targets Recommended: VD/VDR
Results for "

VD/VDR

" in MCE Product Catalog:

38

Inhibitors & Agonists

3

Natural
Products

2

Recombinant Proteins

9

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas
  • HY-15330
    VD2-D3

    VD/VDR Metabolic Disease
    VD2-D3 is a deuterated form of vitamin D.
  • HY-114310
    VDR agonist 1

    VD/VDR Apoptosis Cancer
    VDR agonist 1 (compound 28) is a nonsteroidal Vitamin D receptor (VDR) agonist, with an IC50 of 690 nM in MCF-7 cells. VDR agonist 1 arrests the cell cycle through the up-regulation of p21 and p27, promotes apoptosis by increasing the expression of BAX and decrease the expression of Bcl-2.
  • HY-15328
    25-Hydroxy VD2-D6

    VD/VDR Metabolic Disease
    25-Hydroxy VD2-D6 is a labelled metabolite of Vitamin D2.
  • HY-15327
    1alpha, 25-Dihydroxy VD2-D6

    VD/VDR Metabolic Disease
    1alpha, 25-Dihydroxy VD2-D6 is a deuterated form of vitamin D.
  • HY-12305A
    (R)-Q-VD-OPh

    (R)-QVD-OPH; (R)-Quinoline-Val-Asp-Difluorophenoxymethylketone

    Others Cancer
    (R)-Q-VD-OPh ((R)-QVD-OPH) is the less active enantiomer of Q-VD-OPha. Q-VD-OPha is an irreversible pan-caspase inhibitor with potent antiapoptotic properties.
  • HY-12305
    Q-VD-OPh

    QVD-OPH; Quinoline-Val-Asp-Difluorophenoxymethylketone

    Caspase HIV Cancer Infection
    Q-VD-OPh is an irreversible pan-caspase inhibitor with potent antiapoptotic properties; inhibits caspase 7 with an IC50 of 48 nM and 25-400 nM for other caspases including caspase 1, 3, 8, 9, 10, and 12. Q-VD-OPh can inhibits HIV infection. Q-VD-OPh is able to cross the blood-brain barrier.
  • HY-15156
    1alpha, 24, 25-Trihydroxy VD2

    VD/VDR Metabolic Disease
    1alpha, 24, 25-Trihydroxy VD2 is a vitamin D analog.
  • HY-15157
    Calcitetrol

    1α, 24, 25-Trihydroxy VD3

    VD/VDR Metabolic Disease
    Calcitetrol(1α, 24, 25-Trihydroxy VD3) is the hormonally active form of vitamin D with three hydroxyl groups.
  • HY-76801
    24, 25-Dihydroxy VD2

    24,25-Dihydroxy vitamin D2

    VD/VDR Drug Metabolite Metabolic Disease
    24, 25-Dihydroxy VD2 is a hydroxylated metabolite of Vitamin D2; a synthetic analog of Vitamin D.
  • HY-76915
    24, 25-Dihydroxy VD3

    VD/VDR Endogenous Metabolite Metabolic Disease
    24, 25-Dihydroxy VD3 is a compound which is closely related to 1,25-dihydroxyvitamin D3, the active form of vitamin D3, but like vitamin D3 itself and 25-hydroxyvitamin D3 is inactive as a hormone both in vitro and in vivo.
  • HY-15331
    VD3-D6

    Vitamin D3-26,26,26,27,27,27-d6

    VD/VDR Metabolic Disease
    VD3-D6(Vitamin D3-26,26,26,27,27,27-d6) is the deuterated form of Vitamin D3; tools for determination of Vitamin D3 metabolites in human serum.
  • HY-100219
    CB1151

    VD/VDR Cancer
    CB1151 is a 20-epi analogue of 1,25 dihydroxyvitamin D3 (VD) with potent anti-tumor effects. CB1151 inhibits MCF-7 cell growth with an IC50 value of 0.82 nM.
  • HY-32344
    Inecalcitol

    TX 522

    VD/VDR Apoptosis Cancer
    Inecalcitol (TX 522), a unique vitamin D3 analog, is an orally active vitamin D receptor (VDR) agonist with a Kd of 0.53 nM. Inecalcitol can induce cell apoptosis and has potent anticancer activities.
  • HY-13249
    1alpha-Hydroxy VD4

    1α-Hydroxy vitamin D4

    VD/VDR Cancer
    1alpha-Hydroxy VD4 , a 1alpha(OH)D derivative, can effectively induce the differentiation of monoblastic leukaemia U937, P39/TSU and P31/FUJ cells.
  • HY-12407
    ZK168281

    VD/VDR Metabolic Disease
    ZK168281 is a 25-carboxylic ester 1α,25(OH)2D3 analog and a pure VDR antagonist with a Kd value of 0.1 nM. ZK168281 is an effective inhibitor of the coactivator (CoA) interaction of its receptor.
  • HY-15329
    Maxacalcitol-D6

    VD/VDR Metabolic Disease
    Maxacalcitol-D6 is the deuterated form of Maxacalcitol (22-Oxacalcitriol), which is a non-calcemic vitamin D3 analog and VDR ligand of VDR-like receptors.
  • HY-75035
    Calcipotriol Impurity C

    VD/VDR Inflammation/Immunology
    Calcipotriol Impurity C is the impurity of Calcipotriol, Calcipotriol is a ligand of VDR-like receptors.
  • HY-15265
    Impurity F of Calcipotriol

    VD/VDR Cancer
    Impurity F of Calcipotriol; Calcipotriol (MC 903; Calcipotriene) is a ligand of VDR-like receptors.
  • HY-10002
    Calcitriol

    1,25-Dihydroxyvitamin D3

    VD/VDR Endogenous Metabolite Cancer
    Calcitriol is the most active metabolite of vitamin D and also a vitamin D receptor (VDR) agonist.
  • HY-32339
    Maxacalcitol

    22-Oxacalcitriol

    VD/VDR Metabolic Disease
    Maxacalcitol (22-Oxacalcitriol) is non-calcemic vitamin D3 analog and ligand of VDR-like receptors.
  • HY-15264
    MC 1046

    Impurity A of Calcipotriol

    VD/VDR Cancer
    MC 1046(Impurity A of Calcipotriol) is an impurity of Calcipotriol; Calcipotriol (MC 903; Calcipotriene) is a ligand of VDR-like receptors.
  • HY-15266
    24R-Calcipotriol

    PRI 2202; Impurity D of Calcipotriol

    VD/VDR Cancer
    24R-Calcipotriol(PRI 2202) is an impurity of Calcipotriol; Calcipotriol (MC 903; Calcipotriene) is a ligand of VDR-like receptors.
  • HY-131961
    Triciferol

    VD/VDR HDAC Cancer
    Triciferol functions as a multiple ligand with combined VDR agonist and HDAC antagonist activities. Triciferol binds directly to the VDR (IC50=87 nM), and functions as an agonist with 1,25D-like potency on several 1,25D target genes. Triciferol induces marked tubulin hyperacetylation, and augments histone acetylation. Antiproliferative and cytotoxic activities.
  • HY-32351
    Calcifediol

    25-hydroxy Vitamin D3

    VD/VDR Endogenous Metabolite Metabolic Disease
    Calcifediol (25-hydroxy Vitamin D3), a major circulating metabolite of vitamin D3, is a potent VDR inhibitor.
  • HY-32351A
    Calcifediol monohydrate

    25-hydroxy Vitamin D3 monohydrate

    VD/VDR Endogenous Metabolite Metabolic Disease
    Calcifediol monohydrate (25-hydroxy Vitamin D3 monohydrate), a major circulating metabolite of vitamin D3, is a potent VDR inhibitor.
  • HY-13294
    Impurity C of Alfacalcidol

    VD/VDR Metabolic Disease
    Impurity of Alfacalcidol. Alfacalcidol (1-hydroxycholecalciferol; Alpha D3; 1.alpha.-Hydroxyvitamin D3) is a non-selective VDR activator medication.
  • HY-75041
    Calcitriol Impurities A

    VD/VDR Metabolic Disease
    Calcitriol Impurities A is the impurity of Calcitriol, Calcitriol is the hormonally active form of vitamin D, Calcitriol is the active metabolite of vitamin D3 that activates the vitamin D receptor (VDR).
  • HY-77274
    Calcitriol Impurities D

    VD/VDR Metabolic Disease
    Calcitriol Impurities D is the impurity of Calcitriol, Calcitriol is the hormonally active form of vitamin D, Calcitriol is the active metabolite of vitamin D3 that activates the vitamin D receptor (VDR).
  • HY-10003
    Alfacalcidol

    1-hydroxycholecalciferol; 1.alpha.-Hydroxyvitamin D3

    VD/VDR Metabolic Disease
    Alfacalcidol (1-hydroxycholecalciferol) is a vitamin D active metabolites, acts as a non-selective VDR activator medication, and widely be used in the management of osteoporosis.
  • HY-15332
    Alfacalcidol-D6

    VD/VDR Metabolic Disease
    Alfacalcidol-D6, a deuterated Alfacalcidol (1-hydroxycholecalciferol; Alpha D3; 1.alpha.-Hydroxyvitamin D3), is a non-selective VDR activator medication.
  • HY-13293
    Impurity C of Calcitriol

    VD/VDR Cancer
    Impurity C of Calcitriol, Calcitriol(1,25-Dihydroxyvitamin D3; Rocaltrol ) is the hormonally active form of vitamin D, Calcitriol is the active metabolite of vitamin D3 that activates the vitamin D receptor (VDR).
  • HY-13292
    Impurity B of Calcitriol

    1β,25-Dihydroxyvitamin-D3; 1-Epicalcitriol

    VD/VDR Cancer
    Impurity B of Calcitriol, Calcitriol(1,25-Dihydroxyvitamin D3; Rocaltrol ) is the hormonally active form of vitamin D, Calcitriol is the active metabolite of vitamin D3 that activates the vitamin D receptor (VDR).
  • HY-12398A
    TEI-9648

    VD/VDR Metabolic Disease Inflammation/Immunology
    TEI-9648, a Vitamin D3 Lactone analogue, is a potent and specific vitamin D receptor (VDR) antagonist. TEI-9648 inhibits VDR/VDRE-mediated genomic actions of 1α,25(OH)2D3. TEI-9648 also inhibits HL-60 cell differentiation induced by of 1α,25(OH)2D3. TEI-9648 has the potential for bone metabolism research.
  • HY-76814
    Calcitriol D6

    VD/VDR Metabolic Disease
    Calcitriol D6 is the deuterated form of Calcitriol(1,25-Dihydroxyvitamin D3; Rocaltrol ), which is the hormonally active form of vitamin D, Calcitriol is the active metabolite of vitamin D3 that activates the vitamin D receptor (VDR).
  • HY-12398
    TEI-9647

    VD/VDR Metabolic Disease Inflammation/Immunology
    TEI-9647, a Vitamin D3 Lactone analogue, is a potent and specific vitamin D receptor (VDR) antagonist. TEI-9647 inhibits VDR/VDRE-mediated genomic actions of 1α,25(OH)2D3. TEI-9647 inhibits bone resorption and HL-60 cell differentiation induced by of 1α,25(OH)2D3. TEI-9647 has the potential for suppressing the excessive bone resorption and osteoclast formation in Paget's disease.
  • HY-B0975AS
    Penicillin V-d5

    Bacterial Antibiotic Infection
    Penicillin V-d5 (Phenoxymethylpenicillin-d5) is the deuterium labeled Penicillin V. Penicillin V (Phenoxymethylpenicillin) is an orally active antibiotic. Penicillin V inhibits the growth of Streptococci, C. difficile and S. aureus. Penicillin V can be used for the research of otitis, sinusitis, pharyngitis and tonsillitis.
  • HY-12397
    ZK159222

    VD/VDR Endocrinology
    ZK159222, a 25-carboxylic ester analogue of 1α,25-(OH)2D3, is a potent 1α,25-(OH)2D3 receptor (VDR) antagonist. The mechanism of ZK159222 antagonistic action is mediated by a lack of ligand-induced vitamin D receptor interaction with coactivators. ZK159222 has a partial agonistic character.
  • HY-10002A
    (1S)-Calcitriol

    1α,25-Dihydroxy-3-epi-vitamin-D3

    Others Others
    (1S)-Calcitriol (1α,25-Dihydroxy-3-epi-vitamin-D3) is a natural metabolite of 1α,25-dihydroxyvitamin D3 (1α,25(OH)2D3). (1S)-Calcitriol exhibits potent vitamin D receptor (VDR)-mediated actions such as inhibition of keratinocyte growth or suppression of parathyroid hormone secretion.